Metabolomics analysis elucidates unique influences on purine / pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury

Table 1 Overview of the experimental set-up and plasma biochemical data

	Veh-S	Feb-S	Top-S	Allo-S	Veh-I	Feb-I	Top-I	Allo-I	Veh-R	Feb-R	Top-R	Allo-R
Sampling state	Stationary (under resting state)				30 min left renal ischemia				30 min left renal ischemia + 30 min reperfusion
Administrated drugs	0.5% Methyl-cellulose	10 mg/kg Febu-xostat	10 mg/kg Topiro-xostat	50 mg/kg Allo-purinol	0.5% Methyl-cellulose	10 mg/kg Febu-xostat	10 mg/kg Topiro-xostat	50 mg/kg Allo-purinol	0.5% Methyl-cellulose	10 mg/kg Febu-xostat	10 mg/kg Topiro-xostat	50 mg/kg Allo-purinol
Identification of group
BUN (mg/dl)	16.8 ± 1.6	12.8 ± 1.0	14.7 ± 2.5	16.1 ± 1.4	21.4 ± 2.9 ^$$,&&,##	20.2 ± 2.1 ^$$,&&,#	20.1 ± 3.0 ^$$,&&,##	21.9 ± 3.2 ^*,$$,&&,##	20.2 ± 2.0 ^$$,&&,#	20.3 ± 0.7 ^$$,&&,#	20.5 ± 2.9 ^$$,&&,#	21.2 ± 1.7 ^*,$$,&&,##
Creatinine (mg/dl)	0.26 ± 0.03	0.28 ± 0.03	0.30 ± 0.03	0.28 ± 0.04	0.41 ± 0.04 **^,$$,&,##	0.39 ± 0.05 **^,$$,&,##	0.41 ± 0.05 **^,$$,&&,##	0.43 ± 0.09 **^,$$,&&,##	0.39 ± 0.05 **^,$$,&,##	0.37 ± 0.05 **^,$,##	0.45 ± 0.04 **^,$$,&&,##	0.43 ± 0.06 **^,$$,&&,##
Uric Acid (mg/dl)	0.46 ± 0.17	0.1 > ±N.A	0.1 > ±N.A	0.1 > ±N.A	0.63 ± 0.14*	0.1	0.1 > ±N.A	0.1 > ±N.A	0.54 ± 0.05	0.1	0.1 > ±N.A	0.1

BUN, blood urea nitrogen. Concentrations are expressed as nmol/g wet weight; the data are represented as the mean ± SEM (n = 5/6). *P < 0.05 and **P < 0.01 versus Veh-S; ^$P < 0.05 and ^$$P < 0.01 versus Feb-S; ^&P < 0.05 and ^&&P < 0.01 versus Top-S; ^#P < 0.05 and ^##P < 0.01 versus Allo-S; one-way ANOVA followed by Games–Howell’s test

ISSN: 1528-3658